The status of platinum anticancer drugs in the clinic and in clinical trials.
By N. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun. Dalton Transactions, 2010
1,486 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/55b1f126bf345c8c6660e9ce6ed022606a983c7b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- Cisplatin: The first metal based anticancer drug. (2019, background): “Trials studies for different combination therapies with heptaplatin are known [178].”
- Metal complexes in cancer therapy – an update from drug design perspective (2017, background): “Unfortunately, some platinum-based drugs developed as a result of shortcomings emanating from the clinical use of cisplatin were also associated with severe side effects that had prevented regulatory authorities from granting their marketing approval.(68) Drugs in this class include JM-11 developed ”
- Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (2017, background): “This compound has been found to be effective against various cancer lines, including testicular, ovarian and solid tumours of the head and neck [266–271].”